{
  "docId": "019de076-0505-71be-a3a1-1067f47d4f96",
  "docSlug": "246b804be07776f664c6b3d8600daf3e",
  "documentTitle": "MAIA Biotechnology | Investor Presentation Deck | 39 slides",
  "authorId": "maia-biotechnology",
  "authorName": "MAIA Biotechnology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 39,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide outlines a multi-stage clinical trial design (Part A/B to Part C) involving immune activation with various checkpoint inhibitors.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-0505-71be-a3a1-1067f47d4f96/23",
  "deckHref": "/decks/019de076-0505-71be-a3a1-1067f47d4f96",
  "deckJsonHref": "/decks/019de076-0505-71be-a3a1-1067f47d4f96.json",
  "deckAnchorHref": "/decks/019de076-0505-71be-a3a1-1067f47d4f96#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.96,
        "x": 0.02,
        "y": 0.3
      },
      "kind": "diagram",
      "text": "Flowchart showing Baskets (CRC, HCC, SCLC, Solid Tumors) leading to THIO, then Immune Activation with TECENTRIQ, LIBTAYO, KEYTRUDA, and finally Part C expansion.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae8ba2f2-adb8-4df5-a648-181d3060a67a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.96,
        "x": 0.02,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "A Multicenter, Open-label, Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with Anti-PD-1 or Anti-PD-L1",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea8ecb23-bdfe-4c50-81b3-afe150606112",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1 Dose to be selected from THIO-101 study results\n2 E.g. Breast, Prostate, Gastric, Pancreatic, Ovarian, etc",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "365f9f79-39dd-4caf-8903-f9c967c7091e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "THIO-102 TRIAL (PLANNED)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "701dc781-d83f-44ac-813f-aff950157f67",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "35293d77-2e53-4376-9f33-94cb86ae023d",
      "evidence": "The slide uses a flow-based diagram to illustrate the progression of a clinical trial from initial baskets to a pivotal phase.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}